Insulin-like growth factor binding proteins related to progression-free survival (PFS) and overall survival (OS) in advanced non-small cell lung cancer (NSCLC) patients treated with chemotherapy

被引：2
|
作者：
Karmali, R. [1 ]
Fidler, M. J. [1 ]
Cela, I. [1 ]
Olmsted, G. [1 ]
Rouhi, O. [1 ]
Basu, S. [1 ]
Walters, K. K. [1 ]
Coon, J. [1 ]
Bonomi, P. [1 ]
Borgia, J. A. [1 ]
机构：
[1] Rush Univ, Med Ctr, Chicago, IL 60612 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.7553
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7553
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Progression-free survival (PFS) and overall survival (OS) in phase HI trials of systemic chemotherapy in advanced non-small cell lung cancer (NSCLC).
    Hotta, K.
    Kiura, K.
    Takigawa, N.
    Tabata, M.
    Fujiwara, Y.
    Tanimoto, M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [2] Insulin-like growth factor binding proteins and response in advanced non-small cell lung cancer (NSCLC) patients treated with erlotinib
    Fidler, Mary J.
    Gimelfarb, Alla
    Dehghan-Paz, Irene
    Basu, Sanjib
    Fhied, Christina
    Kaiser-Walters, Kelly A.
    Farlow, Erin C.
    Rouhi, Omid
    Batus, Marta
    Coon, John S.
    Bonomi, Philip
    Borgia, Jeffrey A.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S507 - S508
  • [3] Time trends in overall survival (OS) and progression-free survival (PFS) in the first-line treatment of advanced non-small-cell lung cancer (NSCLC).
    Rutkowski, Jacek
    Saad, Everardo D.
    Buyse, Marc E.
    Jassem, Jacek
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [4] OVERVIEW OF PRIMARY ENDPOINTS, PROGRESSION-FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) FOR NON-SMALL CELL LUNG CANCER (NSCLC): THEIR VALUE IN TREATMENT DECISIONS AND PATIENT CARE
    Heron, Louise
    Chouaid, Christos
    Vergnenegre, Alain
    Bischoff, Helge
    Walzer, Stefan
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1447 - S1448
  • [5] OVERVIEW OF PRIMARY ENDPOINTS, PROGRESSION-FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) FOR NON-SMALL CELL LUNG CANCER (NSCLC): THEIR VALUE IN TREATMENT DECISIONS AND PATIENT CARE
    Heron, L.
    De Castro Carpeno, J.
    Chouaid, C.
    Vergnenegre, A.
    Bischoff, H. G.
    Walzer, S.
    [J]. VALUE IN HEALTH, 2011, 14 (03) : A177 - A178
  • [6] PROGRESSION FREE SURVIVAL (PFS) IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) TREATED ERLOTINIB/GEFITINIB WHO FAILED PREVIOUS CHEMOTHERAPY
    Madolangan, Jamaluddin
    Andarini, Sita Laksmi
    Hudoyo, Achmad
    [J]. RESPIROLOGY, 2014, 19 : 165 - 165
  • [7] THE OVERALL SURVIVAL (OS) AND PROGRESSION-FREE SURVIVAL (PFS) OF HYPERPROGRESSIVE DISEASE (HDP) IN LUNG CANCER PATIENTS
    Oh, Youjin
    Djunadi, Trie Arni
    Chung, Liam Il-Young
    Lee, Soowon
    Hong, Timothy
    Shah, Zunairah
    Park, Joo Hee
    Yoon, Sung Mi
    Duan, Richard
    Chae, Young Kwang
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A1468 - A1469
  • [8] Influence of crossover therapy on the association between progression-free survival (PFS) and overall survival (OS) in randomized trials of molecular-targeted agents for advanced non-small cell lung cancer (NSCLC).
    Hotta, K.
    Kiura, K.
    Suzuki, E.
    Takigawa, N.
    Fujiwara, Y.
    Ichihara, E.
    Tabata, M.
    Tanimoto, M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [9] Impact of clinical and biological markers on progression-free survival (PFS) and overall survival (OS) in patients (pts) with advanced non-small-cell cancer (NSCLC) treated by erlotinib: results of the ERMETIC cohort
    Cadranel, Jacques
    Lizard, Sarah
    Mauguen, Audrey
    Beau-Faller, Michele
    Friard, Sylvie
    Buisine, Marie-Pierre
    Pretet, Jean-luc
    Degeorges, Armelle
    Madelaine, Jeannick
    Chouaid, Christos
    Morin, Franck
    Pignon, Jean-Pierre
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S502 - S503
  • [10] VALUE OF PROGRESSION-FREE SURVIVAL (PFS) IN REFRACTORY NON-SMALL CELL LUNG CANCER (NSCLC): AN EXPLORATORY MODELING ANALYSIS
    Ferrufino, C. P.
    Foley, D.
    Trochlil, K.
    Munakata, J.
    [J]. VALUE IN HEALTH, 2011, 14 (07) : A447 - A447
12345